Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Income from Continuing Operations (2021 - 2025)

Aligos Therapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 19881000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 75.8% year-over-year to 19881000.0; the TTM value through Dec 2025 reached 24193000.0, up 81.56%, while the annual FY2025 figure was 24193000.0, 81.56% up from the prior year.
  • Income from Continuing Operations reached 19881000.0 in Q4 2025 per ALGS's latest filing, up from 31537000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 43088000.0 in Q1 2025 to a low of 82150000.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 23372950.0, with a median of 22420500.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 223.59% in 2025 against a maximum downside of 413.44% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 37714000.0 in 2021, then soared by 41.97% to 21886000.0 in 2022, then fell by 27.44% to 27892000.0 in 2023, then plummeted by 194.53% to 82150000.0 in 2024, then skyrocketed by 75.8% to 19881000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Income from Continuing Operations are 19881000.0 (Q4 2025), 31537000.0 (Q3 2025), and 15863000.0 (Q2 2025).